These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17087143)

  • 1. [Use of erythropoietin in patients with acute renal failure].
    Kes P; Basić-Jukić N; Jurić I
    Lijec Vjesn; 2006; 128(7-8):250-1. PubMed ID: 17087143
    [No Abstract]   [Full Text] [Related]  

  • 2. EPO therapy during acute kidney disease: to use or not to use, that is the question.
    Kraus E; Rabb H
    Am J Kidney Dis; 2005 Nov; 46(5):967-9. PubMed ID: 16253740
    [No Abstract]   [Full Text] [Related]  

  • 3. Erythropoietin and acute renal failure.
    Sharples EJ; Yaqoob MM
    Semin Nephrol; 2006 Jul; 26(4):325-31. PubMed ID: 16949472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of recombinant human erythropoietin in anemia of malignancy.
    Cazzola M
    Med Oncol; 1998 Aug; 15 Suppl 1():S1-2. PubMed ID: 9785329
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biological similarity of erythropoietin: controlled maturation].
    Combe C
    Nephrol Ther; 2009 Feb; 5 Spec No1():1-2. PubMed ID: 19233074
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-dose erythropoietin treatment of anaemia associated with operative transfusion haemolysis and acute renal failure.
    Walter J; Kun K; Doman J
    Nephrol Dial Transplant; 1992; 7(6):559-60. PubMed ID: 1320238
    [No Abstract]   [Full Text] [Related]  

  • 7. Erythropoietin in the critically ill: what is the evidence?
    Corwin HL; Eckardt KU
    Nephrol Dial Transplant; 2005 Dec; 20(12):2605-8. PubMed ID: 16221691
    [No Abstract]   [Full Text] [Related]  

  • 8. An unusual etiology of erythropoietin resistance: hyperthyroidism.
    Kaynar K; Ozkan G; Erem C; Gul S; Yilmaz M; Sonmez B; Ozdemir F; Ulusoy S
    Ren Fail; 2007; 29(6):759-61. PubMed ID: 17763175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting anemia management.
    Dykeman J
    CANNT J; 2002; 12(2):27-9. PubMed ID: 12164020
    [No Abstract]   [Full Text] [Related]  

  • 10. [Anaemia, cardiac failure and erythropoietin].
    Cohen Solal A; Beauvais F
    Arch Mal Coeur Vaiss; 2005 Oct; 98(10):997-1001. PubMed ID: 16294546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Severe, life-threatening renal anemia treatment in patients who do not accept heterologous blood transfusion for religious reasons--case report].
    Jaroszyński AJ; Bober-Palak E; Jóźwiak L; Ksiazek A
    Przegl Lek; 2007; 64(7-8):528-30. PubMed ID: 18409359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anemia in chronic heart failure: etiology and treatment options.
    Westenbrink BD; de Boer RA; Voors AA; van Gilst WH; van Veldhuisen DJ
    Curr Opin Cardiol; 2008 Mar; 23(2):141-7. PubMed ID: 18303527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin and treatment of non-anemic conditions--cardiovascular protection.
    Fliser D; Haller H
    Semin Hematol; 2007 Jul; 44(3):212-7. PubMed ID: 17631185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothyroidism and resistance to human recombinant erythropoietin.
    Touam M; Guéry B; Goupy C; Menoyo V; Drüeke T
    Nephrol Dial Transplant; 2004 Apr; 19(4):1020-1. PubMed ID: 15031379
    [No Abstract]   [Full Text] [Related]  

  • 15. [How to optimize the concept of the variability of haemoglobin in dialysis patients].
    Kessler M
    Nephrol Ther; 2008 Dec; 4(7):547-8. PubMed ID: 18809370
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients.
    Costa E; Swinkels DW; Laarakkers CM; Rocha-Pereira P; Rocha S; Reis F; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
    Acta Haematol; 2009; 122(4):226-9. PubMed ID: 19887781
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of epoetin zeta for correction of renal anemia in hemodialysis patients with thalassemia minor.
    Kumchev E; Koytchev R; Dimitrakov D; Stavrev P; Tsochev G; Siebert-Weigel M
    Adv Ther; 2008 Dec; 25(12):1375-8. PubMed ID: 19043680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia.
    Stoffel MP; Haverkamp H; Kromminga A; Lauterbach KW; Baldamus CA
    Nephron Clin Pract; 2007; 105(2):c90-8. PubMed ID: 17164586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease.
    Fishbane S
    Blood Purif; 2007; 25(1):53-7. PubMed ID: 17170538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing anemia. What do we do now? Views from Canada.
    Mendelssohn DC; Muirhead N; Manns BJ
    Nephrol News Issues; 2007 Jun; 21(7):55-7. PubMed ID: 17623988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.